九典制药(300705) - 2018 Q3 - 季度财报

Financial Performance - Operating revenue for the reporting period reached CNY 200,766,824.48, a 48.85% increase year-on-year[8] - Net profit attributable to shareholders decreased by 24.17% to CNY 16,504,923.95 compared to the same period last year[8] - The net profit after deducting non-recurring gains and losses was CNY 15,222,185.09, down 25.94% year-on-year[8] - Basic earnings per share fell by 46.15% to CNY 0.07[8] - The weighted average return on equity decreased to 2.42%, down 3.64% from the previous year[8] - Total operating revenue for the third quarter reached ¥200.77 million, a significant increase of 48.7% compared to ¥134.88 million in the same period last year[32] - Net profit attributable to the parent company was ¥16.50 million, down 24.0% from ¥21.77 million in the previous year[34] - The company's operating revenue for the current period reached ¥200,766,824.48, a 48.7% increase from ¥134,876,744.17 in the previous period[37] - The net profit for the current period was ¥20,088,430.78, representing an increase of 10.0% compared to ¥18,255,513.11 in the previous period[38] - The total profit for the current period is ¥58,569,585.99, compared to ¥49,810,943.77 in the previous period, showing an increase of about 17.5%[46] Assets and Liabilities - Total assets increased by 10.32% to CNY 848,570,976.22 compared to the end of the previous year[8] - Cash and cash equivalents decreased by 43.72% to ¥167,968,847.89 from ¥298,428,659.93 due to increased long-term asset investments[16] - Accounts receivable increased by 43.53% to ¥117,425,453.71 from ¥81,813,211.04, driven by growth in operating revenue[16] - Fixed assets grew by 77.76% to ¥232,600,425.90 from ¥130,847,828.96, attributed to the completion of construction projects[16] - The total liabilities of the company reached ¥111.39 million, an increase of 49.9% from ¥74.28 million at the beginning of the period[30] - Current liabilities rose to ¥109.93 million, compared to ¥72.62 million at the start of the period, marking an increase of 51.5%[30] - The company's equity attributable to shareholders rose to ¥708.03 million, compared to ¥669.60 million, reflecting an increase of 5.7%[31] Cash Flow - Cash flow from operating activities showed a significant decline of 83.07%, totaling CNY 8,276,965.38 year-to-date[8] - The cash flow from operating activities generated a net amount of ¥8,276,965.38, a decrease from ¥48,875,691.25 in the previous period[47] - The company reported a cash outflow from investment activities of ¥158,901,241.56, compared to an outflow of ¥57,480,113.24 in the previous period[49] - The cash flow from financing activities generated a net amount of ¥20,159,122.14, a significant decrease from ¥261,767,356.24 in the previous period[49] - The net cash flow from financing activities was 20,159,122.14 CNY, compared to 261,767,356.24 CNY in the previous period[53] Expenses - Research and development expenses surged by 95.12% to ¥36,601,631.46 from ¥18,758,767.34, indicating increased investment in new products and technologies[16] - Sales expenses escalated by 157.30% to ¥219,696,637.68 from ¥85,384,813.44 due to intensified product marketing efforts[16] - Research and development expenses for the quarter were ¥17.70 million, which is an increase of 165.5% from ¥6.66 million in the same quarter last year[32] - The total operating costs for the current period were ¥515,458,436.63, compared to ¥300,428,490.47 in the previous period[41] - The company incurred sales expenses of ¥219,696,637.68, significantly higher than ¥85,384,813.44 in the previous period, indicating an increase of approximately 157.5%[45] Shareholder Information - The total number of shareholders at the end of the reporting period was 26,838[12] - The largest shareholder, Zhu Zhihong, holds 37.16% of the shares, totaling 87,210,000 shares[12]